Incyte Blood Cancer Drug Combo Reduces Disease Progression Risk in Aggressive Lymphoma
Incyte's Monjuvi as part of a multi-drug regimen for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death, though with a high side-effect rate.
·1 source
